SEHK:2659Biotechs
Shanghai Bao Pharmaceuticals (SEHK:2659) Revenue Surges 7x While Losses Challenge Bullish Narratives
Shanghai Bao Pharmaceuticals (SEHK:2659) has reported its FY 2025 first half with revenue of C¥42.0 million and a basic EPS loss of C¥3.18, while trailing twelve month figures show revenue of C¥49.2 million against a net loss of C¥395.3 million and EPS of C¥1.36 in the red. Over the past few reporting halves, revenue has moved from C¥1.49 million in 2024 H1 to C¥4.67 million in 2024 H2 and then to C¥42.0 million in 2025 H1, as EPS stayed firmly negative across all periods. This sets up a...